News

Plexxikon, a developer of small molecule pharmaceuticals, has received key composition-of-matter patents covering novel compounds discovered through the company’s Scaffold-based Drug Discovery platform. Two of the three recently

Mr Parkinson will replace David Swetlow, vice president of finance and operations, who is leaving Protox to pursue entrepreneurial opportunities. Previously, Mr Parkinson was vice president of finance

With over 20 years of finance experience, Mr Gardner has held various positions of increasing responsibility in finance both in CFO and controllership roles. Mr Gardner has previously

Dr Hemberger is currently a director of Zymogenetics, Chroma, Atani and Zosano Pharma. Previously, she was a director at Marion Merrell Dow, NeXstar Pharmaceuticals, Pharmion, Perrigo, Myogen and

As chief scientific officer, Dr Barnes will be responsible for all scientific affairs including R&D, product development, process engineering and clinical and regulatory affairs. Dr Barnes will also

Unlike other methods of fracture treatment, the IlluminOss photodynamic bone stabilization system is designed to enable the patient to have immediate joint mobility post procedure without the need

According to OrSense, the NBM-200MP system offers for the first time a non-invasive, continuous and accurate measurement of oxygen saturation under all physiological conditions, as well as a

Net loss for the year ended December 31, 2008 was $59.22 million or $2.01 per share, compared to $52.37 million or $2.10 per share for the prior year

According to CNS Response, the new patent presents novel use of the company’s protected methodology for development of new indications of FDA approved pharmaceuticals when using an EEG